Michal Tal, PhD (@ImmunoFever) header
Michal Tal, PhD (@ImmunoFever) profile picture

Immunoengineer @MITdeptofBE finding new ways to MEASURE and interpret #inflammation #SexDifferences #ChronicLyme #LongCOVID. Mom of 2. prev/ @Yale, @Stanford.

Massachusett land
Joined October 2016
Photo by Michal Tal, PhD (@ImmunoFever)Photo by Michal Tal, PhD (@ImmunoFever)Photo by Michal Tal, PhD (@ImmunoFever)Photo by Michal Tal, PhD (@ImmunoFever)Photo by Michal Tal, PhD (@ImmunoFever)Photo by Michal Tal, PhD (@ImmunoFever)Photo by Michal Tal, PhD (@ImmunoFever)Photo by Michal Tal, PhD (@ImmunoFever)Photo by Michal Tal, PhD (@ImmunoFever)
Finally online - sharing our findings that #Lyme disease bacteria can live in female reproductive organs for over a year and increase risk for gynecological disease!!! We found this increased risk in mice and humans! 😱 (thread below) medrxiv.org/content/10.1101/…
48
271
33
769
100,415
Michal Tal, PhD retweeted
I am a big fan of pubpeer.com - it's the most popular platform for post-publication peer review. Comments are reviewed by volunteer moderators. As part of their website overhaul they now have a statistics page, and it's pretty interesting! pubpeer.com/statistics
1
4
18
712
Which is exactly why we need more (any) approved treatments for the neglected infection-associated chronic illnesses where the standard of care currently is neglect of care. I hear lots of anecdotes of dupixent being helpful. Do you think nemluvio could be even better to trial?
Many said Dupixent would not replace topical steroids…it did. Most said no one will move beyond topical steroids for Opzelura. Wrong. Many said Nemluvio couldn’t push Dupixent out at all. It did in itch. Everyone views current treatments as good enough…until a better treatment comes and then the standard of care becomes neglect of care.
1
8
335
Michal Tal, PhD retweeted
Many said Dupixent would not replace topical steroids…it did. Most said no one will move beyond topical steroids for Opzelura. Wrong. Many said Nemluvio couldn’t push Dupixent out at all. It did in itch. Everyone views current treatments as good enough…until a better treatment comes and then the standard of care becomes neglect of care.
3
13
4
73
8,874
Michal Tal, PhD retweeted
Hilary Mantel went to her doctor at 19 with pain in her legs and her belly, and within a couple of years she was in a psychiatric clinic, on antipsychotics, being advised to stop writing. She was a law student from a mill town in Derbyshire, the first in her family at university, sharp and ambitious. The pain had been coming every month since she was 11. Her GP could find nothing, decided it was nerves, and prescribed antidepressants. When those didn't work she was referred to a psychiatrist. His view was that the trouble was ambition. A girl of her background was straining after too much. He gave her Valium, which made her rage, and when she raged he gave her an antipsychotic. The antipsychotic gave her akathisia, a side effect in which the body cannot keep still and the mind fills with a horror that has no object. She paced, could not sit, could not read. She said afterwards it was the worst thing that ever happened to her. On the ward it was written down as her illness getting worse, and the dose was reviewed accordingly. The more she said the problem was in her body, the surer they became it was in her head. She was told that writing was bad for her. She got herself off the drugs and out of the clinic. A few years later, living in Botswana, she sat down with a medical textbook and worked out the diagnosis herself. She had endometriosis: tissue like the lining of the womb growing through her pelvis and bleeding every month with nowhere to go. By the time a London surgeon opened her up to confirm it she was 27, and the disease had got so far that he took out her womb, her ovaries and sections of her bowel and bladder. She woke up in the menopause. The hormones she was given afterwards changed her body beyond recognition. Then she wrote Wolf Hall and Bring Up the Bodies and became the first woman to win the Booker Prize twice. It took eight years, six doctors and a psychiatric admission to diagnose one of the commonest conditions in women. In the end it was done by the patient, in Africa, with a library book.
60
523
28
2,441
42,186
Michal Tal, PhD retweeted
An extensive prospective assessment of rapid antigen tests for Covid in ~80,000 paired samples w/ PCR tests throughout the pandemic thelancet.com/journals/ebiom… Sensitivity 34.5%; Specificity 99.6% (<-correctly identifies people without Covid) Main influencers: VIral load and symptoms; reduced performance for asymptomatic infections (more w/ Omicron lineages) and in those vaccinated
23
156
30
506
133,672
Michal Tal, PhD retweeted
Occupational solvent exposure and Parkinson’s disease: Exposure to 13 organic solvents by occupational use of at least 100 days. Solvents individually and simultaneously, cumulative exposure by number of solvents and by ten-year age bands before age 50. nature.com/articles/s41598-0…
1
2
9
703
Michal Tal, PhD retweeted
**For kids with ME/CFS! Very interesting clinical report NOT a trial, but a must-read** pubmed.ncbi.nlm.nih.gov/4172… From Dr. Peter Rowe at Johns Hopkins, director of the children's Chronic Fatigue Clinic. All 5 patients in the group improved, some significantly! Full text link next
2
3
14
473
Michal Tal, PhD retweeted
Thanks to funding through Lightcone Commons, I'm auditing millions of papers for issues in text, images, and data. I'm currently scanning ~500,000 supplementary files from Europe PMC and have already found 100+ issues. The plan, and how you can help:
19
25
10
110
6,035
Michal Tal, PhD retweeted
Blood-Based Biomarker Test for Alzheimer in US Practice. 4 plasma BBM tests in adults: sympt of cognitive impairment: Lumipulse G pTau217/Aβ-42, Elecsys pTau181, Elecsys pTau217, PrecivityAD2 combine Aβ42/40 & p-tau217/nonphosphorylated-tau217 ratios jamanetwork.com/journals/jam…
7
16
1,068
Michal Tal, PhD retweeted
Hi everyone, this is the Amatica team posting from Jack’s account. Jack has asked us to share this. Over the past few months Jack’s health has declined significantly. He now has severe muscle weakness that came on quickly, with a burning, lactic-acid-like feeling in his muscles, and he is currently bedbound. He’s focusing on complete rest and on regaining enough function for daily life. We’re supporting Jack as much as we can, and the team is covering his work so he can rest without worrying about it. Any connections to clinicians with experience in severe muscle weakness of rapid onset, please send their details to support@amaticahealth.com. We’ll read everything, though we may not be able to reply to everyone. If you know someone who might be able to help, sharing this post would mean a great deal to us. Until Jack is able to post again himself, we’ll share some of the topics he had prepared, along with occasional updates from the team. Thank you for your support. Nick, Tim, Alex, Kit and Josh
110
167
10
831
29,875
Michal Tal, PhD retweeted
Hypothalamic volume and cell-type changes in ageing and Alzheimer’s. Alterations in metabolism, stress response, sleep, circadian rhythms- neuroendocrine processes are key features of ageing and neurodegeneration- processes regulated by hypothalamus nature.com/articles/s41586-0…
12
22
1,468
I keep wanting to test these erectile dysfunction drugs in the neglected IACIs especially where the capillaries are very short or mostly missing where I think improving blood flow would be tremendously important but not where I see endothelial dysfunction and microhemorrhages.
Did an erectile dysfunction drug just succeed in a Phase 3 Alzheimer's Disease study? The answer is complicated. An intriguing announcement from CTAD 2026 concerns AR1001 (mirodenafil), an oral drug originally developed for erectile dysfunction, now being investigated as a potential treatment for Alzheimer's disease. The earlier Phase 2 trial failed to meet its co-primary clinical efficacy endpoints, and depending on how you interpret the Phase 3 results, this latest study may or may not represent a meaningful success. The Phase 3 POLARIS-AD trial enrolled 1,535 participants with early Alzheimer's disease and evaluated once-daily AR1001 (30 mg) versus placebo over 52 weeks. Before we celebrate, however, there are important reasons for caution. The potential mechanism is fascinating. AR1001 inhibits phosphodiesterase-5 (PDE5), an enzyme that breaks down cyclic guanosine monophosphate (cGMP). By increasing cGMP signaling, the drug may enhance nitric oxide mediated signaling, cerebral blood flow, synaptic plasticity, and cellular pathways involved in learning and memory. There are also hypotheses involving neuroinflammation, tau biology, and neuroprotection, although these mechanisms remain unproven in humans. What did Phase 3 show? In the overall study population, the primary clinical endpoint (CDR-Sum of Boxes) was negative, with a treatment difference of only −0.11 points (P=.4015). However, in a pre-specified monotherapy population of 604 participants who were not receiving background Alzheimer's symptomatic medications, the difference was −0.44 points (P=.0266), described as approximately 31% slowing of clinical decline. Secondary signals included a 0.7-point MMSE advantage (nominal P=.0232), a nonsignificant 1.16-point ADAS-Cog13 advantage (P=.0798), and a reduction in CSF p-tau217 (nominal P=.0402). CSF cGMP also increased, consistent with target engagement, however this does not establish disease modification. Safety appeared broadly comparable for serious adverse events, although diarrhea, dizziness, falls, and treatment discontinuations were more frequent with AR1001. What resonates with me is both the promise and the uncertainty. A prespecified positive population is more compelling than a post hoc subgroup, but it does not erase a negative result in the overall population. We need to understand the statistical hierarchy, multiplicity adjustments, missing data, clinical meaningfulness of a 0.44-point CDR-SB difference, and why background Alzheimer's medications might influence the treatment effect. Importantly, these results have been released through a conference presentation and company announcement, not a full peer-reviewed Phase 3 publication. My message is simple: this is a potentially interesting signal, not yet a reason to declare victory. Alzheimer's disease desperately needs safe, accessible oral therapies, but enthusiasm must be matched by scientific rigor. We must await the full paper and independently scrutinize the data before deciding whether POLARIS-AD was truly a positive trial. neurologylive.com/view/ar100… Phase 2 peer-reviewed publication: pmc.ncbi.nlm.nih.gov/article…
4
5
1
34
1,456
Michal Tal, PhD retweeted
Did an erectile dysfunction drug just succeed in a Phase 3 Alzheimer's Disease study? The answer is complicated. An intriguing announcement from CTAD 2026 concerns AR1001 (mirodenafil), an oral drug originally developed for erectile dysfunction, now being investigated as a potential treatment for Alzheimer's disease. The earlier Phase 2 trial failed to meet its co-primary clinical efficacy endpoints, and depending on how you interpret the Phase 3 results, this latest study may or may not represent a meaningful success. The Phase 3 POLARIS-AD trial enrolled 1,535 participants with early Alzheimer's disease and evaluated once-daily AR1001 (30 mg) versus placebo over 52 weeks. Before we celebrate, however, there are important reasons for caution. The potential mechanism is fascinating. AR1001 inhibits phosphodiesterase-5 (PDE5), an enzyme that breaks down cyclic guanosine monophosphate (cGMP). By increasing cGMP signaling, the drug may enhance nitric oxide mediated signaling, cerebral blood flow, synaptic plasticity, and cellular pathways involved in learning and memory. There are also hypotheses involving neuroinflammation, tau biology, and neuroprotection, although these mechanisms remain unproven in humans. What did Phase 3 show? In the overall study population, the primary clinical endpoint (CDR-Sum of Boxes) was negative, with a treatment difference of only −0.11 points (P=.4015). However, in a pre-specified monotherapy population of 604 participants who were not receiving background Alzheimer's symptomatic medications, the difference was −0.44 points (P=.0266), described as approximately 31% slowing of clinical decline. Secondary signals included a 0.7-point MMSE advantage (nominal P=.0232), a nonsignificant 1.16-point ADAS-Cog13 advantage (P=.0798), and a reduction in CSF p-tau217 (nominal P=.0402). CSF cGMP also increased, consistent with target engagement, however this does not establish disease modification. Safety appeared broadly comparable for serious adverse events, although diarrhea, dizziness, falls, and treatment discontinuations were more frequent with AR1001. What resonates with me is both the promise and the uncertainty. A prespecified positive population is more compelling than a post hoc subgroup, but it does not erase a negative result in the overall population. We need to understand the statistical hierarchy, multiplicity adjustments, missing data, clinical meaningfulness of a 0.44-point CDR-SB difference, and why background Alzheimer's medications might influence the treatment effect. Importantly, these results have been released through a conference presentation and company announcement, not a full peer-reviewed Phase 3 publication. My message is simple: this is a potentially interesting signal, not yet a reason to declare victory. Alzheimer's disease desperately needs safe, accessible oral therapies, but enthusiasm must be matched by scientific rigor. We must await the full paper and independently scrutinize the data before deciding whether POLARIS-AD was truly a positive trial. neurologylive.com/view/ar100… Phase 2 peer-reviewed publication: pmc.ncbi.nlm.nih.gov/article…
2
8
3
33
4,017
The biggest problem that I see is that most of us don't publish our disclose our contradictory data, especially against a big name in the field. This can be for many reasons. 1) life's too short. 2) not worth it (scientifically, no funding or time,...). 3) fear of retaliation.
Today I’m launching what I think could be an extremely important research project. Fixing humanity’s scientific knowledge. The idea is inspired by physicist Casey Handmer, who used AI to screen more than 50,000 papers in theoretical astrophysics. His audit flagged 872 possible errors. This is impressive. But why stop at finding the errors? Let’s use AI to FIX them. And why stop at astrophysics? The ambition of this project is to go through every scientific paper ever published, across every scientific discipline. AI agents will review each article and produce a revised version that corrects the errors they find. The aim is not to shame authors or seek retractions. We are humans and we all make mistakes. The ambition of this project is to correct all the errors that we have made so that current and future generations of scientists can build on firmer foundations. I’m looking for researchers from every discipline to help make this happen. If you’d like to take part, please fill out this short survey and tell me which disciplines you’d like to help cover. Feel free to share with anyone interested. Survey link: unimib.qualtrics.com/jfe/for…
3
1
18
1,164
Michal Tal, PhD retweeted
Today I’m launching what I think could be an extremely important research project. Fixing humanity’s scientific knowledge. The idea is inspired by physicist Casey Handmer, who used AI to screen more than 50,000 papers in theoretical astrophysics. His audit flagged 872 possible errors. This is impressive. But why stop at finding the errors? Let’s use AI to FIX them. And why stop at astrophysics? The ambition of this project is to go through every scientific paper ever published, across every scientific discipline. AI agents will review each article and produce a revised version that corrects the errors they find. The aim is not to shame authors or seek retractions. We are humans and we all make mistakes. The ambition of this project is to correct all the errors that we have made so that current and future generations of scientists can build on firmer foundations. I’m looking for researchers from every discipline to help make this happen. If you’d like to take part, please fill out this short survey and tell me which disciplines you’d like to help cover. Feel free to share with anyone interested. Survey link: unimib.qualtrics.com/jfe/for…
110
97
36
850
50,133
Michal Tal, PhD retweeted
Excited to introduce our latest experiment from @GoogleLabs: Co-Scientist Workbench! Sign up for early access today! labs.google/science/#co-scie…
8
29
276
17,143
Michal Tal, PhD retweeted
Our new paper is out today in Nature Communications! We identify a STING–IFN–CH25H lipid axis linking innate immunity to tau pathology. Deleting Ch25h reduced tau aggregation and protected against neurodegeneration in female tauopathy mice. nature.com/articles/s41467-0…
1
20
1
81
6,522
Michal Tal, PhD retweeted
As presented at #CTAD2026: OpenScientist, an open-source AI co-scientist, reproduced expert findings and generated testable hypotheses across expert-evaluated biomedical studies, including air-gapped runs on open-weight models. dlvr.​it/TWM9kb
7
14
1
46
5,991
Michal Tal, PhD retweeted
Eine Schweizer Studie hat gezeigt, dass die wichtigste Ursache für virale Ansteckung in Schulen nicht enger Kontakt ist, sondern schlechte Belüftung. Liegt der CO2-Wert über 1000 ppm (schnell erreicht), verdoppelt sich das Ansteckungsrisiko beinahe. 4/ nature.com/articles/s41467-0…
16
451
16
1,136
36,141